Chronic Spontaneous Urticaria Csu clinical trials

Explore recruiting chronic spontaneous urticaria csu clinical trials.

Recruiting chronic spontaneous urticaria csu studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Spontaneous Urticaria Csu trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.

Hungary, Latvia, Bulgaria, Slovakia, Poland, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial): a multicentre, randomized, open-label, non-inferiority trial.

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Sympomatic Despite Treatment with H1 Antihistamines and/or Omalizumab, or who Cannot Tolerate Omalizumab

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Poland, Germany, Spain, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 2a OPEN-LABEL BASKET STUDY TO EVALUATE SAFETY AND PHARMACOKINETICS OF INF904, AN ORAL C5aR1 INHIBITOR, IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA OR HIDRADENITIS SUPPURATIVA

Greece, Poland, Germany, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Spontaneous Urticaria Csu trials by city

Chronic Spontaneous Urticaria Csu in Toronto Chronic Spontaneous Urticaria Csu in Vancouver Chronic Spontaneous Urticaria Csu in Montreal Chronic Spontaneous Urticaria Csu in Calgary Chronic Spontaneous Urticaria Csu in Edmonton Chronic Spontaneous Urticaria Csu in Ottawa Chronic Spontaneous Urticaria Csu in Winnipeg Chronic Spontaneous Urticaria Csu in Quebec City Chronic Spontaneous Urticaria Csu in Hamilton Chronic Spontaneous Urticaria Csu in Kitchener Chronic Spontaneous Urticaria Csu in London Chronic Spontaneous Urticaria Csu in Halifax Chronic Spontaneous Urticaria Csu in New York Chronic Spontaneous Urticaria Csu in Los Angeles Chronic Spontaneous Urticaria Csu in Chicago Chronic Spontaneous Urticaria Csu in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease